Table 1. Clinical characteristics of the population involved in the study.
| Characteristics | |
|---|---|
| Age (median) | 50 (30-55) |
| Males, % | 57 |
| BMI | 27.4 (19.3-41.8) |
| Diabetes mellitus, % | 25 |
| SAH, % | 68 |
| Smoking, % | 67 |
| Positive FH for CAD, % | 15 |
| Dyslipidemia, % | 43 |
| Use of illicit drugs, % | 3 |
| Thrombophilias, % | 2 |
| Stable angina, % | 13 |
| Heart failure, % | 3 |
| Prior AMI, % | 27 |
| Prior CABG, % | 10 |
| Prior PTCA, % | 21 |
| Hemoglobin, g/dL | 14.35±1.91 |
| Creatinine, mg/dL | 1.35±1.54 |
| Troponin (peak), ng/dL | 13.70±51.58 |
| LVEF, % | 42.73±23.46 |
| ASA, % | 95 |
| Betablocker, % | 71 |
| Enoxaparin, % | 77 |
| Clopidogrel, % | 59 |
| ACEI, % | 60 |
| Statin, % | 83 |
BMI: body mass index; SAH: systemic arterial hypertension; FH: family history; CAD: coronary artery disease; AMI: acute myocardial infarct; CABG: myocardial revascularization; PTCA: percutaneous coronary angioplasty; LVEF: left ventricle ejection fraction; ASA: acetylsalicylic acid; ACEI: angiotensin-converting enzyme inhibitor.